Triptans for Migraine: Which One Works Best for You?
TL;DR
- Seven triptans are approved for acute migraine, but sumatriptan, rizatriptan, eletriptan, and zolmitriptan account for the vast majority of prescriptions and clinical trial data.
- No single triptan is universally "best." Choice depends on how fast you need relief, whether you can swallow a tablet during nausea, and your cardiovascular risk profile.
- Subcutaneous sumatriptan remains the fastest-acting option (~10–15 minutes to onset); rizatriptan 10 mg and eletriptan 40 mg consistently rank among the best oral triptans for pain-free response at two hours.
- All triptans are contraindicated in uncontrolled hypertension, coronary artery disease, prior stroke, and hemiplegic migraine.
- If triptans fail or are contraindicated, newer CGRP receptor antagonists (gepants) or CGRP monoclonal antibodies offer effective alternatives.
What Are Triptans and How Do They Work?
Migraine is not simply a bad headache. It is a complex neurovascular disorder affecting roughly 12–15% of the global adult population, with a two-to-three-fold higher prevalence in women than men (Global Burden of Disease, 2019). A triptans comparison for migraine relief is one of the most common pharmacotherapy discussions in neurology and primary care alike.
Triptans — selective serotonin 5-HT₁B/1D receptor agonists — were introduced in the early 1990s and rapidly became the gold-standard acute treatment for moderate-to-severe migraine attacks. Their mechanism of action is threefold:
- Cranial vasoconstriction. Activation of 5-HT₁B receptors on intracranial blood vessels reverses the pathological vasodilation that accompanies migraine.
- Inhibition of trigeminal nociceptive transmission. 5-HT₁D receptor activation on trigeminal nerve terminals reduces release of pro-inflammatory neuropeptides, including calcitonin gene–related peptide (CGRP) and substance P.
- Central brainstem modulation. Triptans inhibit signal relay in the trigeminocervical complex, dampening pain processing at the level of the brainstem.
The clinical result: reduced headache intensity, diminished associated symptoms (nausea, photophobia, phonophobia), and restored functional ability — ideally within two hours of dosing.
Seven triptans have been approved by the FDA and EMA: sumatriptan, rizatriptan, eletriptan, zolmitriptan, naratriptan, almotriptan, and frovatriptan. This article focuses on the four most widely prescribed and most extensively studied — sumatriptan, rizatriptan, eletriptan, and zolmitriptan — and provides a head-to-head comparison of their clinical profiles.
Head-to-Head Comparison: Sumatriptan vs Rizatriptan vs Eletriptan vs Zolmitriptan
The landmark meta-analysis by Ferrari et al. (2002), encompassing 53 clinical trials and over 24,000 patients, remains the most comprehensive quantitative comparison of oral triptans. Subsequent Cochrane systematic reviews for individual agents have reinforced these findings. The table below distills the key clinical parameters.
Triptan Comparison Table
| Parameter | Sumatriptan (Imitrex) | Rizatriptan (Maxalt) | Eletriptan (Relpax) | Zolmitriptan (Zomig) |
|---|---|---|---|---|
| Standard oral dose | 50–100 mg | 10 mg | 40 mg | 2.5–5 mg |
| Available formulations | Oral tablet, nasal spray (10/20 mg), subcutaneous injection (4/6 mg), nasal powder (Onzetra Xsail) | Oral tablet, orally disintegrating tablet (ODT) | Oral tablet only | Oral tablet, ODT, nasal spray (2.5/5 mg) |
| Onset of action (oral) | 30–60 min | 30–45 min | 30–60 min | 30–60 min |
| Time to peak plasma (oral) | ~2–2.5 h | ~1–1.5 h | ~1.5–2 h | ~2–3 h |
| 2-hour headache relief | ~59% (100 mg) | ~67–77% (10 mg) | ~65% (40 mg); ~54% (20 mg) | ~65% (2.5 mg) |
| 2-hour pain-free response | ~29% (100 mg) | ~40–45% (10 mg) | ~35% (40 mg) | ~30% (2.5 mg) |
| Sustained pain-free (24 h) | ~20% (100 mg) | ~25–30% (10 mg) | ~25–28% (40 mg) | ~22% (2.5 mg) |
| Headache recurrence (24 h) | ~30–35% | ~30–40% | ~20–25% | ~25–30% |
| Half-life | ~2.5 h | ~2–3 h | ~4–5 h | ~2.5–3 h |
| Metabolism | MAO-A | MAO-A | CYP3A4 | CYP1A2, MAO-A |
| Dose with propranolol | No adjustment | Reduce to 5 mg | No adjustment | No adjustment |
Sources: Ferrari et al. (2002); individual Cochrane systematic reviews; FDA-approved prescribing information.
Key takeaways from the data:
- Rizatriptan 10 mg consistently demonstrates the highest two-hour pain-free rates among oral triptans, along with a relatively rapid onset. The Cochrane review by Oldman et al. confirmed an NNT (number needed to treat) of approximately 3 for pain-free at two hours.
- Eletriptan 40 mg offers the longest half-life of this group and the lowest headache recurrence rate — a meaningful advantage for patients with prolonged attacks.
- Sumatriptan remains the most versatile triptan owing to its range of formulations. While oral sumatriptan is modestly less effective than rizatriptan, the subcutaneous injection is the single most effective acute migraine treatment available, with pain-free rates exceeding 50% at one hour.
- Zolmitriptan provides a middle-ground profile with the added advantage of an intranasal formulation, which bypasses first-pass metabolism and can be useful when nausea limits oral dosing.
The Fastest-Acting Triptan: Route Matters More Than Molecule
When patients ask for the fastest acting triptan, the answer depends less on which triptan and more on how it is delivered.
Ranked by speed of onset:
- Subcutaneous sumatriptan (6 mg) — onset within 10–15 minutes; peak effect at ~20 minutes. This is the fastest route for any triptan and produces the highest response rates across all clinical trials. The Cochrane review by Derry et al. (2014) reported an NNT of 2.1 for headache relief at one hour.
- Intranasal zolmitriptan (5 mg) — onset within 15–20 minutes. Some absorption occurs transmucosally, providing faster relief than the swallowed fraction alone.
- Intranasal sumatriptan (20 mg) — onset within 15–30 minutes. However, much of the dose is swallowed and absorbed gastrointestinally, limiting the speed advantage over oral forms.
- Oral rizatriptan ODT (10 mg) — the orally disintegrating formulation does not absorb transmucosally but is convenient during nausea-related aversion to swallowing. Pharmacokinetic onset is equivalent to the standard tablet (~30 min).
- Oral eletriptan (40 mg) / oral sumatriptan (100 mg) — standard oral onset of 30–60 minutes.
Practical advice: If migraine attacks escalate rapidly and reach peak intensity within 30 minutes, a non-oral formulation (subcutaneous or intranasal) is generally more appropriate than any oral triptan. The American Headache Society (AHS) consensus statement recommends matching formulation to attack characteristics — including speed of onset, presence of nausea, and prior treatment response.
Dosing Guide: How to Use Triptans Effectively
Correct dosing is essential both for efficacy and for minimizing medication-overuse headache (MOH). Below is a practical triptan dosing guide for the four major agents.
Triptan Dosing Table
| Triptan | Route | Starting dose | Maximum single dose | Maximum 24-hour dose | Redosing interval | Key dosing notes |
|---|---|---|---|---|---|---|
| Sumatriptan | Oral | 25–50 mg | 100 mg | 200 mg | ≥2 hours | Take at first sign of pain, not during aura |
| Nasal spray | 10–20 mg | 20 mg | 40 mg | ≥2 hours | One spray per nostril or both in one | |
| Subcutaneous | 4–6 mg | 6 mg | 12 mg (two injections) | ≥1 hour | Autoinjector; rotate injection sites | |
| Rizatriptan | Oral / ODT | 5–10 mg | 10 mg | 30 mg (per FDA label) | ≥2 hours | Use 5 mg if taking propranolol |
| Eletriptan | Oral | 20–40 mg | 40 mg | 80 mg | ≥2 hours | Avoid with strong CYP3A4 inhibitors |
| Zolmitriptan | Oral / ODT | 1.25–2.5 mg | 5 mg | 10 mg | ≥2 hours | Reduce dose in moderate hepatic impairment |
| Nasal spray | 2.5–5 mg | 5 mg | 10 mg | ≥2 hours | Bitter taste common |
Sources: FDA-approved prescribing information for each agent.
Practical Dosing Principles
- Treat early. Triptans are most effective when taken during mild-to-moderate pain, before central sensitization develops. Once cutaneous allodynia (scalp tenderness, discomfort from wearing glasses or earrings) sets in, oral triptan efficacy drops significantly.
- Do not use during the aura phase. Triptans have not shown benefit when taken before pain onset, and early use during aura may theoretically worsen vasoconstriction.
- Redose cautiously. If the first dose provides partial relief but headache returns, a second dose may be taken after the minimum interval. If the first dose provides no relief at all, a second dose of the same triptan within the same attack is unlikely to help.
- Limit use to ≤9 days per month. Using triptans more frequently increases the risk of medication-overuse headache, a secondary chronic daily headache disorder. NICE guideline CG150 specifies that patients should be counseled about this risk at the point of prescribing.
- Combination with naproxen. The combination of sumatriptan 85 mg plus naproxen sodium 500 mg (available as a fixed-dose tablet) has shown superior efficacy to either agent alone in Cochrane analysis (Law et al., 2016). This strategy addresses both the serotonergic and inflammatory components of migraine.
Side Effects and Tolerability
Triptans share a common adverse-effect profile rooted in their serotonergic and vasoconstrictive activity. Most side effects are transient and self-limiting.
Common side effects (occurring in >5% of patients):
- Triptan sensations — chest tightness, pressure, heaviness, tingling in the extremities, and neck stiffness. These occur in roughly 5–15% of oral triptan users and up to 40% with subcutaneous sumatriptan. Despite being alarming to patients, they are generally benign and not cardiac in origin.
- Fatigue and drowsiness — particularly with zolmitriptan and naratriptan.
- Dizziness — reported across all triptans at similar rates.
- Injection-site reactions — pain, redness, and swelling with subcutaneous sumatriptan (~60% of users).
- Dysgeusia (taste disturbance) — common with intranasal formulations, especially zolmitriptan nasal spray.
- Nausea — may be difficult to distinguish from migraine-associated nausea; rates are low (~5%) in controlled trials.
Comparative tolerability: Eletriptan and rizatriptan are generally considered the best-tolerated oral triptans, with lower rates of triptan sensations compared to sumatriptan 100 mg. Sumatriptan at the 50 mg dose has a more favorable side-effect profile than the 100 mg dose, with only a modest reduction in efficacy.
Contraindications and Drug Interactions
All triptans share absolute contraindications related to their vasoconstrictive properties. This is the single most important safety consideration in prescribing.
Contraindications and Interaction Table
| Contraindication / Interaction | Clinical Concern | Applies To |
|---|---|---|
| Ischemic heart disease, coronary vasospasm (Prinzmetal angina) | Risk of coronary vasoconstriction and myocardial ischemia | All triptans |
| Uncontrolled hypertension | Exacerbation of cardiovascular risk | All triptans |
| Prior stroke or TIA | Cerebrovascular vasospasm risk | All triptans |
| Peripheral vascular disease | Worsening of ischemia | All triptans |
| Hemiplegic or basilar migraine | Theoretical risk of prolonged neurological deficit | All triptans |
| Use within 24 hours of another triptan or ergotamine | Additive vasospasm | All triptans |
| MAO-A inhibitors (e.g., moclobemide, phenelzine) | Impaired triptan metabolism → toxicity | Sumatriptan, rizatriptan, zolmitriptan |
| Propranolol co-administration | Increased rizatriptan exposure via MAO-A inhibition | Rizatriptan — reduce dose to 5 mg |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) | Doubled eletriptan plasma levels | Eletriptan — avoid combination |
| Cimetidine co-administration | Increased zolmitriptan half-life (~50%) | Zolmitriptan — consider dose reduction |
| SSRIs / SNRIs | Theoretical serotonin syndrome risk (FDA warning, 2006); subsequent analysis suggests very low absolute risk | All triptans — monitor; risk is low with standard doses |
A note on serotonin syndrome: In 2006, the FDA issued an alert regarding the combined use of triptans with SSRIs or SNRIs. However, subsequent reviews — including the AHS position statement and pharmacoepidemiological analyses — have concluded that the absolute risk of serotonin syndrome from this combination is very low. Most headache specialists continue to prescribe triptans alongside antidepressants, with appropriate patient counseling about warning signs (agitation, hyperthermia, clonus, hyperreflexia).
Special Populations
Pregnancy and Lactation
Migraine often improves during pregnancy, particularly in the second and third trimesters, but when attacks do occur, treatment options are limited. Sumatriptan has the most pregnancy exposure data of any triptan, primarily from pregnancy registries (notably the Sumatriptan/Naratriptan/Treximet Pregnancy Registry). Available data have not demonstrated a consistent increase in major birth defects above the baseline population rate of 3–5%.
- ACOG and AHS guidelines generally classify sumatriptan as an option for moderate-to-severe migraine in pregnancy when non-pharmacological measures and acetaminophen have failed, especially in the second and third trimesters.
- Sumatriptan is minimally excreted into breast milk. The AAP considers it compatible with breastfeeding. A pump-and-discard strategy for 8–12 hours post-dose has historically been advised but is increasingly considered unnecessary given the low infant exposure.
- Data for rizatriptan, eletriptan, and zolmitriptan in pregnancy are more limited. When a triptan is needed during pregnancy, sumatriptan is the preferred first-line agent.
Adolescents (12–17 years)
Almotriptan (12.5 mg) and rizatriptan (5–10 mg based on weight) are FDA-approved for adolescents aged 12 and older. Zolmitriptan nasal spray is approved for ages 12 and up in some jurisdictions. Sumatriptan nasal spray is widely used off-label in this age group with supporting trial evidence.
Elderly Patients (>65 years)
Triptans are generally not recommended as first-line therapy in patients over 65 due to increasing prevalence of cardiovascular disease, hypertension, and the declining incidence of migraine with advancing age. If used, careful cardiovascular risk assessment is essential. NICE CG150 advises against initiating triptans in patients with established cardiovascular risk factors without specialist input.
Hepatic Impairment
Eletriptan and zolmitriptan undergo significant hepatic metabolism and may require dose reduction or avoidance in moderate-to-severe hepatic impairment. Sumatriptan subcutaneous injection, which bypasses hepatic first-pass metabolism, may be preferable in this population.
When to Consider CGRPs Instead of Triptans
The arrival of calcitonin gene–related peptide (CGRP)–targeted therapies has expanded acute and preventive migraine treatment options substantially. Two classes are relevant:
Small-molecule CGRP receptor antagonists (gepants) for acute use:
- Ubrogepant (Ubrelvy) — oral, 50 or 100 mg; FDA-approved 2019.
- Rimegepant (Nurtec ODT) — oral disintegrating tablet, 75 mg; FDA-approved for both acute treatment and prevention.
When to consider a gepant over a triptan:
- Cardiovascular contraindications to triptans — gepants have no vasoconstrictive activity and are not contraindicated in cardiovascular disease.
- Triptan non-responders — approximately 30–40% of patients do not achieve satisfactory relief with triptans. Gepants work via a different mechanism and may succeed where triptans fail.
- Medication-overuse headache risk — current data suggest that gepants have a lower propensity to cause MOH than triptans, though long-term data are still accruing.
- Poor tolerability of triptans — patients who experience significant triptan sensations, fatigue, or other bothersome effects.
- Need for dual acute and preventive therapy — rimegepant is uniquely approved for both acute and every-other-day preventive use.
The AHS consensus statement (2021) positions gepants as appropriate first-line alternatives when triptans are contraindicated or ineffective, rather than as universal replacements. Triptans remain the first-line acute treatment for most patients with moderate-to-severe migraine based on decades of efficacy data, broad formulation options, and generic availability with lower cost.
CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) are preventive therapies — they are not used for acute attacks but may reduce the need for acute medication by decreasing migraine frequency.
Red Flags — When to Seek Immediate Medical Care
Seek emergency medical attention if you experience any of the following during or after taking a triptan:
- Severe, crushing chest pain or chest tightness that does not resolve within minutes — this could indicate a rare cardiac event.
- Signs of serotonin syndrome — agitation, confusion, rapid heart rate, high fever, muscle rigidity, or jerking movements — especially if taking an SSRI/SNRI concurrently.
- Sudden severe headache unlike any previous migraine ("thunderclap headache") — this requires urgent evaluation to exclude subarachnoid hemorrhage or other secondary causes.
- New neurological deficits — weakness, speech difficulty, visual loss, or severe vertigo that persist beyond your typical aura duration.
- Signs of allergic reaction — hives, facial/throat swelling, difficulty breathing.
- Ischemic colitis symptoms — severe abdominal pain, bloody diarrhea (rare but reported with triptans).
Additionally, consult your prescriber if:
- Your migraines are increasing in frequency and you are using triptans more than 8–9 days per month.
- Your usual triptan dose no longer provides adequate relief.
- You develop new cardiovascular risk factors (hypertension, diabetes, smoking, hyperlipidemia) that may alter the risk-benefit profile of continued triptan use.
Frequently Asked Questions
Which triptan works best for migraine?
There is no single "best triptan for migraine" that works for everyone. In clinical trials, rizatriptan 10 mg and eletriptan 40 mg consistently show the highest pain-free response rates among oral triptans. However, individual response varies — approximately 30% of patients who fail one triptan will respond to a different one. Guidelines recommend trying at least two or three different triptans (or formulations) before concluding that triptans are ineffective.
What is the difference between sumatriptan vs rizatriptan?
Sumatriptan is available in the widest range of formulations (oral, nasal, subcutaneous injection), making it the most versatile triptan. Rizatriptan is oral-only but has a faster time to peak plasma concentration and higher two-hour pain-free rates in head-to-head trials. Rizatriptan also offers an orally disintegrating tablet convenient for patients with severe nausea. However, rizatriptan requires dose reduction when taken with propranolol, whereas sumatriptan does not.
Can I take a triptan with ibuprofen or naproxen?
Yes. Combining a triptan with an NSAID is a well-supported strategy. The combination of sumatriptan plus naproxen sodium has demonstrated superior efficacy to either drug alone in randomized controlled trials and is available as a fixed-dose combination product. Taking ibuprofen or naproxen alongside other triptans is common clinical practice, though formal combination trials are fewer.
How many days per month can I safely use triptans?
Most guidelines recommend limiting triptan use to no more than 9 days per month to reduce the risk of medication-overuse headache. NICE CG150 specifically advises warning patients about this risk at the point of prescribing. If you find yourself needing acute treatment more frequently, discuss preventive therapy with your provider.
Are triptans safe to use with antidepressants (SSRIs/SNRIs)?
The FDA issued a warning in 2006 about theoretical serotonin syndrome risk with this combination. However, the AHS and subsequent pharmacoepidemiological data indicate that the absolute risk is very low with standard therapeutic doses. Most headache specialists continue to prescribe triptans alongside SSRIs/SNRIs with appropriate counseling. Monitor for symptoms such as agitation, confusion, rapid heartbeat, and muscle rigidity.
Can I use a triptan if the first dose doesn't work?
If a first dose provides partial relief but the headache returns, a second dose after the recommended interval (usually ≥2 hours) is appropriate. If the first dose provides no relief at all, a second dose of the same triptan during the same attack is generally not effective. In that scenario, consider rescue therapy with an NSAID, antiemetic, or — for severe attacks — discuss alternative options with your clinician.
Why does my migraine come back after the triptan wears off?
This is called headache recurrence and occurs in 20–40% of triptan-treated attacks, typically 4–24 hours after the initial dose. It is more common with shorter-acting triptans (sumatriptan, rizatriptan) and less common with longer-acting agents (eletriptan). Combining a triptan with a long-acting NSAID (naproxen) can reduce recurrence rates. If recurrence is a consistent problem, consider switching to eletriptan or adding naproxen to your regimen.
Should I switch from triptans to CGRP medications?
Not necessarily. Triptans remain effective, well-studied, and affordable first-line treatments. CGRP-targeted therapies (gepants) are most appropriate when triptans are contraindicated due to cardiovascular disease, when triptans are ineffective despite adequate trials, or when side effects are intolerable. Discuss with your healthcare provider whether a switch or adjunctive approach makes sense for your situation.
References
-
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675. PMID: 11728541
-
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults — overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;(5):CD009108. PMID: 24865446
-
Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database Syst Rev. 2007;(1):CD003221. PMID: 17253490
-
Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;(5):CD008616. PMID: 24865448
-
Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev. 2016;(4):CD008541. PMID: 27096438
-
American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1–18. PMID: 30536394
-
NICE. Headaches in over 12s: diagnosis and management. Clinical guideline CG150. 2012 (updated 2021). nice.org.uk/guidance/cg150
-
FDA. Label: Imitrex (sumatriptan succinate) injection, tablets, and nasal spray. 2013. accessdata.fda.gov
-
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019;381(23):2230–2241. PMID: 31800988
-
Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache. 2014;54(7):1158–1172. PMID: 24805878
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in community, hospital, and ambulatory care pharmacy practice. He has a particular interest in neurological and pain pharmacotherapy, evidence-based medicine, and translating clinical guidelines into clear, patient-centered information. Dr. Ozarchuk writes for PillsCard.com, a global drug encyclopedia, where he produces evidence-based medication guides reviewed against current clinical standards. He holds active pharmacy licensure and maintains ongoing continuing education in pharmacotherapy and clinical toxicology.
Medical Disclaimer
The information provided in this article is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on PillsCard.com. If you think you may have a medical emergency, call your doctor, go to the emergency department, or call emergency services immediately. PillsCard.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in its articles.